Good MorningTech and financial stocks led today’s rally after a batch of upbeat earnings reports and analyst upgrades spurred buyers into sector ETFs. Investors cheered strong mid-year numbers from banks and software firms, while hyperscalers such as Amazon, Microsoft, and Meta reiterated hefty data-center buildout plans for 2025, fueling further interest in AI-linked names. Disney’s third-quarter profit beat and McDonald’s traffic boost from its value-focused McValue menu also lifted consumer-oriented shares, as the market looked past soft industry-wide foot traffic.
On the geopolitical front, President Trump announced a fresh 25% tariff on Indian imports of Russian oil—raising the total to 50%—and welcomed Apple’s pledge to invest an additional $100 billion in U.S. operations over four years. Brazil formally requested World Trade Organization consultations over the new tariffs, adding another layer of international friction. Despite these headwinds, solid corporate results kept equities modestly higher into the close. Featured: A Trump Order Could Send This $7 Stock Soaring (Ad) 
|
Markets | | | President Donald Trump on Thursday imposed once unthinkably high U.S. taxes on imports from dozens of countries, part of his campaign to turn one of the world’s most open economies into a fortress bristling with barriers to trade Read the Full Story |
|
From Our Partners | | James Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presidential decision in modern history. According to his research, this could set off a massive wealth wave—potentially turning a $900 investment into $108,000 in under a year.
It has nothing to do with tariffs or trade wars—but it’s already gaining momentum, and the window to act is closing fast. | | Click here to discover the full details of Trump’s “Great Gain” strategy. |
|
Stocks | | | U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump’s tariffs taking effect on dozens of countries had only a muted effect on markets worldwide.The S&P 500 slipped 0.1% after briefly climbing to the cusp of its all-time high during the morning. The Dow Jones Industrial A... Read the Full Story |
|
Markets | | |
Following a recent rally of 20.5%, shares of Celsius Holdings Inc. (NASDAQ: CELH) are gaining popularity again, especially as the stock reaches 90% of its 52-week high and shows enough momentum to potentially push investors toward a new peak for the year. However, there is one major speed bum... Read the Full Story |
|
From Our Partners | | Investing Legend Hints the End May be Near for These 3 Iconic Stocks
One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. | | Click to get the full details on Eric Fry's "Nvidia alternative" right here. |
|
Markets | | | President Donald Trump began imposing higher import taxes on dozens of countries Thursday just as the economic fallout of his monthslong tariff threats has begun to cause visible damage to the U.S. economy.Just after midnight, goods from more than 60 countries and the European Union became subject t... Read the Full Story |
|
Markets | | |
It’s been quite the week for Blade Air Mobility Inc. (NASDAQ: BLDE). On August 4, Blade and Joby Aviation Inc. (NYSE: JOBY) announced the sale of Blade’s passenger mobility business to Joby for up to $125 million. That sent BLDE stock soaring 30%. Blade will become a pure-play m... Read the Full Story |
|
From Our Partners | | Investing Legend Hints the End May be Near for These 3 Iconic Stocks
Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast. | | Click to get the full details on Eric Fry's "Nvidia alternative" right here. |
|
Markets | | | President Donald Trump signed an executive order Wednesday to place an additional 25% tariff on India for its purchases of Russian oil, bringing the combined tariffs imposed by the United States on its ally to 50%.The tariffs would go into effect 21 days after the signing of the order, meaning that ... Read the Full Story |
|
Markets | | |
The Walt Disney Company (NYSE: DIS) faces headwinds in 2025, as do most businesses, but the Q2 results reveal the enduring strength of the brand and the impact of Bob Iger’s return. While revenue headwinds persist for this entertainment company, the company continues to grow, and profitabi... Read the Full Story |
|
Markets | | |
In the world of cloud computing, a market famously dominated by tech titans like Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), and Google (NASDAQ: GOOG), it’s easy to assume there is little room for smaller players. Their immense scale and sprawling service catalogs often define the conve... Read the Full Story |
|
Stocks | | |
Online casino and sports betting firm Rush Street Interactive Inc. (NYSE: RSI) has been one of the biggest surprises of the second-quarter earnings period. The company's impressive earnings report sent shares skyrocketing by nearly 22% in the span of just five days.
With major wins for bot... Read the Full Story |
|
Markets | | | A focus on value — along with hot products like a “Minecraft”-themed meal — helped McDonald’s turn around its sagging sales in the second quarter.McDonald's Chairman and CEO Chris Kempczinski said Wednesday that the company's McValue menu, which was introduced in January, is bringing some U.S. traff... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
